US Patent

US11744816 — Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

Method of Use · Assigned to Esperion Therapeutics Inc · Expires 2036-03-14 · 10y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions and methods for using fixed doses of ETC-1002 and ezetimibe to treat or reduce the risk of cardiovascular disease.

USPTO Abstract

Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.

Drugs covered by this patent

Nexletol (BEMPEDOIC ACID) · Esperion Theraps Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3883`	—	Nexletol
`U-3883`	—	Nexletol

Patent Metadata

Patent number: US11744816
Jurisdiction: US
Classification: Method of Use
Expires: 2036-03-14
Drug substance claim: No
Drug product claim: No
Assignee: Esperion Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.